This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
United Nations General Assembly. Universal Declaration of Human Rights 217 A (III); https://go.nature.com/3jFTm4p (1948).
United Nations General Assembly. International Covenant on Economic, Social and Cultural Rights 2200A (XXI); https://go.nature.com/3ImjL1A (1966).
Swindells, S. et al. N. Engl. J. Med. 380, 1001–1011 (2019).
Sterling, T. R. et al. N. Engl. J. Med. 365, 2155–2166 (2011).
Dorman, S. E. et al. N. Engl. J. Med. 384, 1705–1718 (2021).
Turkova, A. et al. N. Engl. J. Med. 386, 911–922 (2022).
Conradie, F. et al. N. Engl. J. Med. 387, 810–823 (2022).
Nyang’wa, B. T. et al. N. Engl. J. Med. 387, 2331–2343 (2022).
Farmer, P. Am. J. Pub. Health 89, 1486–1496 (1999).
Farmer, P. E. N. Engl. J. Med. 369, 2424–2436 (2013).
J.F. received grant funding from the Stop TB Partnership’s Global Drug Facility to support the rollout of child-friendly formulations of second-line drugs. M.P. has no financial or industry conflicts to disclose; he serves as an advisor to the WHO, Foundation for Innovative New Diagnostics, Stop TB Partnership and Bill & Melinda Gates Foundation. B.-T.N. is employed by Médecins Sans Frontières, the sponsor of the TB-PRACTECAL trial that developed a 6-month multidrug-resistant/rifampicin-resistant TB (RR-/MDR-TB) regimen. Through grants to her institution, C.D.M. receives research funding to study all-oral shortened regimens for treatment of drug-resistant TB containing bedaquiline, delamanid, linezolid, clofazimine, levofloxacin, moxifloxacin and pyrazinamide.
Rights and permissions
About this article
Cite this article
McKenna, L., Frick, M., Angami, K. et al. The 1/4/6x24 campaign to cure tuberculosis quickly. Nat Med 29, 16–17 (2023). https://doi.org/10.1038/s41591-022-02136-z